GSK Sees Excedrin Sales Growth As Consumers Visualize Headache Pain
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
Excedrin Extra Strength US sales for the 12 months ending Aug. 12 were up 4.07% to $77.2m, but those figures don't include the 12,000 free packages of Excedrin gel tablets consumers ordered during GSK's the Limited Edition promotion. The firm offered Excedrin in packages marked with causes consumers commonly link with headaches: commuting, bad dating and "adulting."